References
- Beard JR, Officer A, de Carvalho IA, et al. The world report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145–2154. doi:10.1016/S0140-6736(15)00516-426520231
- Dang JW, Wang YY, Liu NN. The Fourth Survey Report on the Living Conditions of China’s Urban and rural Older Persons; 2018.
- Li HZ, Yang X, Zhu Y, et al. The general research report of chinese strategic for dealing with population aging. Sci Res Aging. 2015;3(3):4–35.
- China NHaFPCo. China Health Statistics Yearbook 2013. National Health and Family Planning Commission of the People’s Republic of China; 2014.
- Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J. 1992;13:34–42. doi:10.1093/eurheartj/13.suppl_g.34
- Jissho S, Shimada K, Taguchi H, et al. Impact of electrocardiographic left ventricular hypertrophy on the occurrence of cardiovascular events in elderly hypertensive patients. Circ J. 2010;74(5):938–945. doi:10.1253/circj.cj-09-072220339195
- Okin PM, Hille DA, Kjeldsen SE, Devereux RB. Combining ECG criteria for left ventricular hypertrophy improves risk prediction in patients with hypertension. J Am Heart Assoc. 2017;6:11. doi:10.1161/JAHA.117.007564
- Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566. doi:10.1056/NEJM1990053132222032139921
- Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140(6):848–856. doi:10.1067/mhj.2000.11111211099987
- Antikainen RL, Peters R, Beckett NS, et al. Left ventricular hypertrophy is a predictor of cardiovascular events in elderly hypertensive patients: hypertension in the very elderly trial. J Hypertens. 2016;34(11):2280–2286. doi:10.1097/HJH.000000000000107327552643
- Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898. doi:10.1056/NEJMoa080136918378519
- Bai K, Pan Y, Lu F, Zhao Y, Wang J, Zhang L. Kidney function and cognitive decline in an oldest-old Chinese population. Clin Interv Aging. 2017;12:1049–1054. doi:10.2147/CIA.S13420528740370
- Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging. 2001;18(3):151–164. doi:10.2165/00002512-200118030-0000111302283
- Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/ASN.200604036816988059
- Havranek EP, Froshaug DB, Emserman CD, et al. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med. 2008;121(10):870–875. doi:10.1016/j.amjmed.2008.05.03418823858
- Bang CN, Soliman EZ, Simpson LM, et al. Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the ALLHAT study. Am J Hypertens. 2017;30(9):914–922.28430947
- Shenasa M, Shenasa H. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol. 2017;237:60–63. doi:10.1016/j.ijcard.2017.03.00228285801
- Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. doi:10.1136/bmj.i448227599725
- Strauss DG. Differentiation between left bundle branch block and left ventricular hypertrophy: Implications for cardiac resynchronization therapy. J Electrocardiol 2012;45(6):635–9.23022304
- Smiseth OA, Aalen JM. Mechanism of harm from left bundle branch block. Trends Cardiovasc Med. 2019;29(6):335-342. doi:10.1016/j.tcm.2018.10.012